Metformin/Rosuvastatin Combination Therapy With in Patients With Type 2 Diabetes and Dyslipidemia

A Multi-center, Randomized, Double-blind, Phase III Clinical Trial to Compare the Efficacy and Safety of Metformin/Rosuvastatin Combination Therapy With Metformin or Rosuvastatin Monotherapy in Patients With Type 2 Diabetes and Dyslipidemia

Compare the Efficacy and Safety of Metformin/Rosuvastatin Combination Therapy With Metformin or Rosuvastatin Monotherapy in Patients With Type 2 Diabetes and Dyslipidemia

Multi-center, Randomized, Double-blind, Phase III clinical trial

Inclusion Criteria:

• Over 19 years
• Type II DM with Dyslipidemia
• 6.5% ≤ HbA1c < 11%
• Triglyceride < 350mg/dL
• 100mg/dL ≤ LDL-C ≤ 250mg/dL
• FPG ≤ 270mg/dL

Exclusion Criteria:

• Type I DM
• Unstable angina, MI, Stroke, CABG with 6 month from screening
• SBP ≥ 180mmHg, DBP ≥ 110mmHg
• TSH > UNL
• Heart failure (NYHA class III/IV)
• Serum Creatinine > UNL or CLCr < 60 mL/min
• CK ≥ 2x UNL
• HIV positive
• BMI > 40 kg/m^2